| __timestamp | Eli Lilly and Company | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 4932500000 | 1656170000 |
| Thursday, January 1, 2015 | 5037200000 | 2003565000 |
| Friday, January 1, 2016 | 5654900000 | 2137539000 |
| Sunday, January 1, 2017 | 6070200000 | 2166062000 |
| Monday, January 1, 2018 | 4681700000 | 2437164000 |
| Tuesday, January 1, 2019 | 4721200000 | 2757459000 |
| Wednesday, January 1, 2020 | 5483300000 | 3084873000 |
| Friday, January 1, 2021 | 7312800000 | 2970522000 |
| Saturday, January 1, 2022 | 6629800000 | 3832437000 |
| Sunday, January 1, 2023 | 7082200000 | 4269276000 |
| Monday, January 1, 2024 | 8418299999 |
In pursuit of knowledge
In the pharmaceutical industry, understanding cost dynamics is crucial for strategic planning. Eli Lilly and Company, a leader in innovative medicines, and Grifols, S.A., a global healthcare company, have shown distinct trends in their cost of revenue from 2014 to 2023. Over this period, Eli Lilly's cost of revenue increased by approximately 44%, peaking in 2021 with a notable 30% jump from the previous year. This surge reflects their aggressive expansion and investment in new drug development. Meanwhile, Grifols experienced a steady rise, with a 158% increase over the same period, highlighting their growing market presence and operational scaling. The data reveals that while Eli Lilly's costs fluctuate, Grifols maintains a consistent upward trajectory, indicating different strategic approaches in managing production and operational expenses.
Analyzing Cost of Revenue: Eli Lilly and Company and GSK plc
Cost Insights: Breaking Down Eli Lilly and Company and Pfizer Inc.'s Expenses
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Eli Lilly and Company and BeiGene, Ltd.
Eli Lilly and Company vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Grifols, S.A.
Cost Insights: Breaking Down Eli Lilly and Company and Bausch Health Companies Inc.'s Expenses
Cost Insights: Breaking Down Merck & Co., Inc. and Grifols, S.A.'s Expenses
Cost of Revenue Comparison: Biogen Inc. vs Grifols, S.A.
Grifols, S.A. vs Alkermes plc: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Grifols, S.A. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Grifols, S.A. vs MiMedx Group, Inc.